Balyasny Asset Management LLC Esperion Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

$54.8 Billion
Q1 2024

A detailed history of Balyasny Asset Management LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 159,038 shares of ESPR stock, worth $353,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

159,038

Previous 37,188 327.66%

Holding current value

$353,064

Previous $111,000 283.78%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.02 - $3.02 $246,137 - $367,987	121,850 Added 327.66%	159,038 $426,000
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $27,147 - $114,539	37,188 New	37,188 $111,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $5.71 Million - $8.37 Million	-4,755,321 Reduced 99.66%	16,039 $22,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $1.96 Million - $9.8 Million	1,342,223 Added 39.14%	4,771,360 $7.59 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $13.4 Million - $22.4 Million	2,633,466 Added 330.97%	3,429,137 $21.4 Million

Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $4.27 Million - $6.37 Million	783,700 Added 6546.65%	795,671 $5.33 Million
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $239,983 - $335,574	-50,311 Reduced 80.78%	11,971 $76,000
Q2 2020 Aug 14, 2020	SELL	$30.04 - $51.31 $5.99 Million - $10.2 Million	-199,456 Reduced 76.2%	62,282 $3.2 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $311,745 - $838,896	11,361 Added 4.54%	261,738 $8.25 Million
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $4.08 Million - $6.89 Million	115,147 Added 85.15%	250,377 $14.9 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $903,734 - $1.25 Million	-26,218 Reduced 16.24%	135,230 $4.96 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $6.08 Million - $7.93 Million	151,554 Added 1531.78%	161,448 $7.51 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $1.28 Million - $1.61 Million	-31,330 Reduced 76.0%	9,894 $439,000
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $3.95 Million - $8.34 Million	-109,217 Reduced 72.6%	41,224 $1.62 Million
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $16.7 Million - $20.4 Million	-252,723 Reduced 62.68%	150,441 $10.9 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $435,308 - $675,244	10,014 Added 2.55%	403,164 $26.5 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $17.2 Million - $20.7 Million	393,150	393,150 $19.7 Million

Others Institutions Holding ESPR

# of Institutions

174

Shares Held

125M

Call Options Held

2.08M

Put Options Held

1.01M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $148M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Esperion Therapeutics, Inc. Transaction History